Khalid Islam is an entrepreneur and businessperson who founded 6 companies, which include: Gain Therapeutics, Inc., Sirius Healthcare Partners GmbH and BioAim LLC and who has been at the helm of 13 different companies. Presently, he is Chairman for Fennec Pharmaceuticals, Inc., Chairman of Minoryx Therapeutics SL, Chairman for Gain Therapeutics, Inc. (which he founded in 2017), Chairman for GT Gain Therapeutics SA (a subsidiary of Gain Therapeutics, Inc.) and Managing Director at Life Sciences Management GmbH (which he founded in 2014).

He is also on the board of Processa Pharmaceuticals, Inc. and Advisor at Kurma Biofund FCPR and Partner at Sirius Healthcare Partners GmbH (he founded the company in 2009).

He previously held the position of Chairman at Caerus Consulting AS, Chairman at Ki Consulting AG (he founded the company in 2010), Chairman for Arpida, Inc., Chairman for Pcovery ApS, Chairman for Adenium Biotech ApS, Chairman at Adenium AB, Chairman & Chief Executive Officer of Gentium Srl, President, Chief Executive Officer & Director at Arpida AG, Head-Biotechnology at Marion Merrell Dow (Europe) AG, Team Leader & Manager-Alliance at Hoechst Marion Roussel Group and Professor at the University of Milan.

Khalid Islam received an undergraduate degree from Chelsea College and a doctorate from Imperial College London.